<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00606892</url>
  </required_header>
  <id_info>
    <org_study_id>HIC # 0702002338</org_study_id>
    <secondary_id>MIRECC 000000000</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <secondary_id>R01DA014537</secondary_id>
    <nct_id>NCT00606892</nct_id>
  </id_info>
  <brief_title>Varenicline and Nicotine Interactions in Humans (VA)</brief_title>
  <official_title>Varenicline Attenuates Some of the Subjective and Physiological Effects of Intravenous Nicotine in Humans.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine the effects of varenicline on the subjective, physiological and cognitive
      responses to intravenous nicotine. Varenicline is a partial nicotine agonist and it is
      approved as a treatment for smoking cessation. We predict that varenicline treatment will
      modify subjective, physiological and cognitive responses to IV nicotine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a 2-4 week double-blind, placebo-controlled study. Twenty four male and female
      smokers will have two 4-day treatment periods, in which they will be randomized to
      varenicline (1 mg/day) or placebo. During the first 3 days of each treatment period, smokers
      will have daily clinic visits and receive their study medication. On Day 4, subjects will
      come to the laboratory, where they will receive ascending doses of intravenous (IV) nicotine
      (0.1, 0.4, and 0.7 mg per 70kg). This procedure will allow accurate assessment of varenicline
      effects on the subjective, physiological and cognitive responses to nicotine. Following a
      washout period, subjects will be crossed over to the alternative treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective Responses to Intravenous Nicotine</measure>
    <time_frame>30 minutes after each nicotine infusion</time_frame>
    <description>The Drug Effects Questionaire( DEQ) is a 7-item psychometric that measures the following subjective categories: 'drug strength',' high', 'feels stimulated', 'good effects', 'bad effects', 'head rush', and 'like the drug'. Smokers rated each item on a 100 millimeter scale from &quot;not at all&quot; (a score of 0) to &quot;extremely&quot; with a maximum score of 100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Reaction Time (RT) on Modified Stroop Task.</measure>
    <time_frame>pre-nicotine, and 30 min after last nicotine infusion (Post-Nicotine)</time_frame>
    <description>A Modified stroop task was used to assess attentional responses to smoking and negative affect cues. Cues were presented as blue, red or green text. Subjects completed 2 counterbalanced blocks (60 trials per block). One block contained smoking cues and neutral cues. The other block contained negative affect cues and a different set of matched neutral cues. The 2 blocks were administered twice during each experimental session - prior to nicotine infusion, and 30 mins after the last nicotine infusion (2 hrs and 45 mins after medication dosing). The Stroop effect is a differential RT when identifying the colors of words presented as neutral cues vs. emotional cues (i.e. smoking or negative affect cues).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cotinine Levels</measure>
    <time_frame>Before each laboratory session on day 5</time_frame>
    <description>Subject Cotinine Levels before each laboratory session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>30 minutes after each nicotine infusion</time_frame>
    <description>The average peak change (change score = maximum post dose score minus predose baseline) in heart rate was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Systolic and Diastolic Blood Pressure</measure>
    <time_frame>30 minutes after each nicotine infusion</time_frame>
    <description>The average peak change (change score = maximum post dose score minus predose baseline) in systolic and diastolic blood pressure after nicotine infusion.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Placebo First, varenicline, + IV Nic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received a Placebo tablet once per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1, 0.4, and 0.7 mg per 70 kg).After a minimum of a 5 day washout subjects then received varenicline tablet (1mg). once per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1,0.4,0.7 mg per 70kg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Varenicline first, placebo, + IV Nic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Varenicline tablet (1 mg) per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1, 0.4, and 0.7 mg per 70 kg). After a washout of a minimum of 5 days subjects then received placebo tablet for per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1,0.4,, and 0.7mg per 70 kg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>Varenicline (1 mg per day) given for 4 days prior to laboratory session</description>
    <arm_group_label>Placebo First, varenicline, + IV Nic</arm_group_label>
    <arm_group_label>Varenicline first, placebo, + IV Nic</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar Pill</description>
    <arm_group_label>Placebo First, varenicline, + IV Nic</arm_group_label>
    <arm_group_label>Varenicline first, placebo, + IV Nic</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Nic</intervention_name>
    <description>IV Nicotine given during the laboratory session following 4 days of exposure to the study medication (varenicline or placebo). This nicotine was given during each laboratory session which followed the 4 days of exposure to either placebo then varenicline or varenicline then placebo.</description>
    <arm_group_label>Placebo First, varenicline, + IV Nic</arm_group_label>
    <arm_group_label>Varenicline first, placebo, + IV Nic</arm_group_label>
    <other_name>IV Nicotine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female and male smokers, aged 18 to 55 years

          -  History of smoking daily for the past 12 months, at least 15 cigarettes daily

          -  Carbon Monoxide (Alveolar) level &gt; 10ppm

          -  For women: not pregnant as determined by pregnancy screening, nor breast feeding, and
             using acceptable birth control methods

        Exclusion Criteria:

          -  History of heart disease, renal or hepatic diseases

          -  other medical conditions that the physician investigator deems as contraindicated for
             the subject to be in the study

          -  Regular use of psychotropic medication (antidepressants, antipsychotics, or
             anxiolytics)

          -  recent psychiatric diagnosis and treatment for Axis I disorders including

          -  major depression, bipolar affective disorder,

          -  schizophrenia and panic disorder within the past year

          -  Current dependence on alcohol

          -  drugs or treatments for drug

          -  alcohol addiction within the past 5 years

          -  Allergy to varenicline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehmet Sofuoglu, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University Associate Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veterans Affairs Hospital</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Sofuoglu M, Herman AI, Mooney M, Waters AJ. Varenicline attenuates some of the subjective and physiological effects of intravenous nicotine in humans. Psychopharmacology (Berl). 2009 Nov;207(1):153-62. doi: 10.1007/s00213-009-1643-z. Epub 2009 Aug 20.</citation>
    <PMID>19693492</PMID>
  </results_reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2008</study_first_submitted>
  <study_first_submitted_qc>February 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2008</study_first_posted>
  <results_first_submitted>March 14, 2012</results_first_submitted>
  <results_first_submitted_qc>September 9, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 25, 2014</results_first_posted>
  <last_update_submitted>September 9, 2014</last_update_submitted>
  <last_update_submitted_qc>September 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>therapeutic effects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the New Haven Connecticut area through newspaper advertisements and fliers from the summer of 2007 thru the winter of 2008.</recruitment_details>
      <pre_assignment_details>There was no special pre-assignment procedures for this study. Thirty seven smokers signed a consent form with only 17 randomized. 13 smokers never return to clinic after signing a consent form. 2 smokers were excluded secondary to poor IV access. 5 smokers had dropped out due to a scheduling conflict.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo First, Then Varenicline</title>
          <description>Subject received a placebo tablet once per day for 4 days and then received a laboratory session where they were given ascending dose of Nicotine (0.1,0.4, and 0.7mg per70kg). After a minimum washout period of 5 days,then subjects received Varenicline (1mg) per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1, 0.4, and 0.7mg per 70kg).</description>
        </group>
        <group group_id="P2">
          <title>Varenicline First, Then Placebo</title>
          <description>Subjects received Varenicline (1mg) per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1, 0.4, and 0.7mg per 70kg).After a minimum of washout period of 5 days, then subjects received a placebo tablet once per day for 4 days and then received a laboratory session where they were given ascending dose of Nicotine (0.1,0.4, and 0.7mg per70kg).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Adaptation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>37 subjects signed consent. 17 subjects received the first treatment. Five subjects dropped out due to non-compliance with study procedures prior to study completion, and therefore were not included in the analysis. The 12 subjects who completed both interventions were included in the analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Includes all subjects who completed the study. (The total number of subjects who were enrolled in both arms of the study.)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.0" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Mean Reaction Time (RT) on Modified Stroop Task.</title>
        <description>A Modified stroop task was used to assess attentional responses to smoking and negative affect cues. Cues were presented as blue, red or green text. Subjects completed 2 counterbalanced blocks (60 trials per block). One block contained smoking cues and neutral cues. The other block contained negative affect cues and a different set of matched neutral cues. The 2 blocks were administered twice during each experimental session - prior to nicotine infusion, and 30 mins after the last nicotine infusion (2 hrs and 45 mins after medication dosing). The Stroop effect is a differential RT when identifying the colors of words presented as neutral cues vs. emotional cues (i.e. smoking or negative affect cues).</description>
        <time_frame>pre-nicotine, and 30 min after last nicotine infusion (Post-Nicotine)</time_frame>
        <population>Data from all subjects who completed both experimental sessions (nicotine infusion after 4 days of placebo and also 4 days of varneicline, n=12) are presented. RT's &lt; 100 ms, or &gt; 1501 ms were excluded from the analysis (&gt;3 SD's of the mean). The data presented are the mean RT's to identifying word colors under each treatment condition.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo, Pre-Nicotine</title>
            <description>Mean reaction time during modified Stroop task under the placebo condition and prior to the nicotine infusions.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Post-Nicotine</title>
            <description>Mean reaction time during modified Stroop task under the placebo condition and 30 minutes after the nicotine infusions.</description>
          </group>
          <group group_id="O3">
            <title>Varenicline, Pre-Nicotine</title>
            <description>Mean reaction time during modified Stroop task under the varenicline condition prior to the nicotine infusions.</description>
          </group>
          <group group_id="O4">
            <title>Varenicline, Post-Nicotine</title>
            <description>Mean reaction time during modified Stroop task under the varenicline condition and 30 minutes after the nicotine infusions.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Reaction Time (RT) on Modified Stroop Task.</title>
          <description>A Modified stroop task was used to assess attentional responses to smoking and negative affect cues. Cues were presented as blue, red or green text. Subjects completed 2 counterbalanced blocks (60 trials per block). One block contained smoking cues and neutral cues. The other block contained negative affect cues and a different set of matched neutral cues. The 2 blocks were administered twice during each experimental session - prior to nicotine infusion, and 30 mins after the last nicotine infusion (2 hrs and 45 mins after medication dosing). The Stroop effect is a differential RT when identifying the colors of words presented as neutral cues vs. emotional cues (i.e. smoking or negative affect cues).</description>
          <population>Data from all subjects who completed both experimental sessions (nicotine infusion after 4 days of placebo and also 4 days of varneicline, n=12) are presented. RT's &lt; 100 ms, or &gt; 1501 ms were excluded from the analysis (&gt;3 SD's of the mean). The data presented are the mean RT's to identifying word colors under each treatment condition.</population>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Smoking Block</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="722.3" spread="131.3"/>
                    <measurement group_id="O2" value="693.1" spread="129.4"/>
                    <measurement group_id="O3" value="660.1" spread="137.8"/>
                    <measurement group_id="O4" value="624.2" spread="100.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral Block- Smoking Cue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="702.3" spread="148.6"/>
                    <measurement group_id="O2" value="686.7" spread="134.1"/>
                    <measurement group_id="O3" value="652.1" spread="115.5"/>
                    <measurement group_id="O4" value="618.6" spread="104.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Affect block</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="679.0" spread="104.1"/>
                    <measurement group_id="O2" value="641.3" spread="114.9"/>
                    <measurement group_id="O3" value="665.8" spread="177.1"/>
                    <measurement group_id="O4" value="631.7" spread="128.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral Block- Negative Affect Cue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="692.5" spread="117.5"/>
                    <measurement group_id="O2" value="661.5" spread="111.1"/>
                    <measurement group_id="O3" value="644.8" spread="122.8"/>
                    <measurement group_id="O4" value="618.6" spread="108.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A mixed-effect repeated-measures crossover model with fixed main effect terms of treatment (placebo or varenicline) and time of measurement (Pre-Nicotine or Post-Nicotine) was utilized. Interactions between main effect terms were also analyzed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Significant treatment or treatment-by-time interactions were followed up by post hoc comparisons of placebo vs. varenicline for time (Pre- vs. Post-Nicotine infusion) and testing block (Smoking Block vs. Negative Affect Block).</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cotinine Levels</title>
        <description>Subject Cotinine Levels before each laboratory session.</description>
        <time_frame>Before each laboratory session on day 5</time_frame>
        <population>Subjects finishing the complete study. (n=12)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>The mean cotinine levels for subjects under the placebo condition.</description>
          </group>
          <group group_id="O2">
            <title>Varenicline (1 mg)</title>
            <description>The mean cotinine levels for subjects under the varenicline condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Cotinine Levels</title>
          <description>Subject Cotinine Levels before each laboratory session.</description>
          <population>Subjects finishing the complete study. (n=12)</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202" spread="41"/>
                    <measurement group_id="O2" value="185" spread="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.3</p_value>
            <method>ANOVA</method>
            <method_desc>F(1,10)=1.1</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>17</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>40</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subjective Responses to Intravenous Nicotine</title>
        <description>The Drug Effects Questionaire( DEQ) is a 7-item psychometric that measures the following subjective categories: 'drug strength',' high', 'feels stimulated', 'good effects', 'bad effects', 'head rush', and 'like the drug'. Smokers rated each item on a 100 millimeter scale from &quot;not at all&quot; (a score of 0) to &quot;extremely&quot; with a maximum score of 100.</description>
        <time_frame>30 minutes after each nicotine infusion</time_frame>
        <population>All participants who complete all interventions.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/ Low Dose Nictoine</title>
            <description>The average peak change (change score) in the subjective responses to the 7-items of the DEQ to the low dose (0.1) of IV nicotine under the placebo condition.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/ Medium Dose Nicotine</title>
            <description>The average peak change (change score) in the subjective responses to the 7-items of the DEQ to the medium dose (0.4) of IV nicotine under the placebo condition.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/High Dose Nicotine</title>
            <description>The average peak change (change score) in the subjective responses to the 7-items of the DEQ to the high dose (0.7) of IV nicotine under the placebo condition.</description>
          </group>
          <group group_id="O4">
            <title>Varenicline/ Low Dose Nicotine</title>
            <description>The average peak change (change score) in the subjective responses to the 7-items of the DEQ to the low dose (0.1) of IV nicotine under the varenicline condition.</description>
          </group>
          <group group_id="O5">
            <title>Varenicline/ Medium Dose Nicotine</title>
            <description>The average peak change (change score) in the subjective responses to the 7-items of the DEQ to the medium dose (0.4) of IV nicotine under the varenicline condition.</description>
          </group>
          <group group_id="O6">
            <title>Varenicline/ High Dose Nicotine</title>
            <description>The average peak change (change score) in the subjective responses to the 7-items of the DEQ to the high dose (0.7) of IV nicotine under the varenicline condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Responses to Intravenous Nicotine</title>
          <description>The Drug Effects Questionaire( DEQ) is a 7-item psychometric that measures the following subjective categories: 'drug strength',' high', 'feels stimulated', 'good effects', 'bad effects', 'head rush', and 'like the drug'. Smokers rated each item on a 100 millimeter scale from &quot;not at all&quot; (a score of 0) to &quot;extremely&quot; with a maximum score of 100.</description>
          <population>All participants who complete all interventions.</population>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" spread="8"/>
                    <measurement group_id="O2" value="38" spread="10"/>
                    <measurement group_id="O3" value="51" spread="10"/>
                    <measurement group_id="O4" value="14" spread="4"/>
                    <measurement group_id="O5" value="27" spread="7"/>
                    <measurement group_id="O6" value="37" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head Rush</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" spread="8"/>
                    <measurement group_id="O2" value="40" spread="9"/>
                    <measurement group_id="O3" value="51" spread="9"/>
                    <measurement group_id="O4" value="11" spread="4"/>
                    <measurement group_id="O5" value="28" spread="7"/>
                    <measurement group_id="O6" value="37" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feels Stimulated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" spread="8"/>
                    <measurement group_id="O2" value="34" spread="10"/>
                    <measurement group_id="O3" value="38" spread="10"/>
                    <measurement group_id="O4" value="11" spread="4"/>
                    <measurement group_id="O5" value="24" spread="8"/>
                    <measurement group_id="O6" value="35" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug Strength</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" spread="8"/>
                    <measurement group_id="O2" value="41" spread="9"/>
                    <measurement group_id="O3" value="58" spread="09"/>
                    <measurement group_id="O4" value="16" spread="4"/>
                    <measurement group_id="O5" value="32" spread="7"/>
                    <measurement group_id="O6" value="40" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bad Effects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="3"/>
                    <measurement group_id="O2" value="15" spread="7"/>
                    <measurement group_id="O3" value="23" spread="8"/>
                    <measurement group_id="O4" value="8" spread="3"/>
                    <measurement group_id="O5" value="8" spread="3"/>
                    <measurement group_id="O6" value="20" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good Effects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" spread="8"/>
                    <measurement group_id="O2" value="30" spread="8"/>
                    <measurement group_id="O3" value="45" spread="10"/>
                    <measurement group_id="O4" value="22" spread="8"/>
                    <measurement group_id="O5" value="25" spread="8"/>
                    <measurement group_id="O6" value="34" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Like the Drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" spread="8"/>
                    <measurement group_id="O2" value="27" spread="9"/>
                    <measurement group_id="O3" value="35" spread="10"/>
                    <measurement group_id="O4" value="14" spread="4"/>
                    <measurement group_id="O5" value="25" spread="8"/>
                    <measurement group_id="O6" value="35" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A mixed-effect repeated-measures crossover model including fixed main effects for treatment condition (placebo or varenicline), time of measurement and interactions between treatment and time, was utilized. Because multiple measurements were collected before and after each nicotine dose, a change score (maximum post dose score - pre dose baseline) was used in the analysis.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Values of p&lt;0.05 were considered statistically significant, based on 2-tailed tests. Significant treatment, or treatment-by-time interactions were followed by post hoc comparisons. To account for multiple testing, significance was set at p&lt;0.016.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate</title>
        <description>The average peak change (change score = maximum post dose score minus predose baseline) in heart rate was calculated.</description>
        <time_frame>30 minutes after each nicotine infusion</time_frame>
        <population>Changes in heart rate, systolic and diastolic blood pressure during the experimental sessions were analyzed on all subjects who completed both experimental sessions (n=12).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Low Dose Nicotine</title>
            <description>The average peak change (change score) in heart rate after nicotine (0.1mg per70kg) infusion under the placebo condition.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/ Medium Dose Nicotine</title>
            <description>The average peak change (change score) in heart rate after nicotine (0.4mg per 70kg) infusion under the placebo condition.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/High Dose Nicotine</title>
            <description>The average peak change (change score) in heart rate after nicotine (0.7mg per 70kg) infusion under the placebo condition.</description>
          </group>
          <group group_id="O4">
            <title>Varenicline/ Low Dose Nicotine</title>
            <description>The average peak change (change score) in heart rate after nicotine (0.1mg per 70kg) infusion under the varenicline condition.</description>
          </group>
          <group group_id="O5">
            <title>Varenicline/ Medium Dose Nicotine</title>
            <description>The average peak change (change score) in heart rate after nicotine (0.4mg per 70kg) infusion under the varenicline condition.</description>
          </group>
          <group group_id="O6">
            <title>Varenicline / High Dose Nicotine</title>
            <description>The average peak change (change score) in heart rate after nicotine (0.7mg per 70kg) infusion under the varenicline condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate</title>
          <description>The average peak change (change score = maximum post dose score minus predose baseline) in heart rate was calculated.</description>
          <population>Changes in heart rate, systolic and diastolic blood pressure during the experimental sessions were analyzed on all subjects who completed both experimental sessions (n=12).</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="1"/>
                    <measurement group_id="O2" value="13" spread="2"/>
                    <measurement group_id="O3" value="16" spread="2"/>
                    <measurement group_id="O4" value="2" spread="2"/>
                    <measurement group_id="O5" value="5" spread="1"/>
                    <measurement group_id="O6" value="5" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A mixed-effect, repeated-measures, crossover model was used with fixed main effects for treatment (placebo or varenicline), and time after treatment. Interactions between main effects were also analyzed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Post hoc comparisons of effects of varenicline versus placebo for different nicotine doses were performed and significance was adjusted for multiple testing using a p value of P&lt;0.016</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Two-tailed tests were applied for main effects with P&lt;0.05</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Systolic and Diastolic Blood Pressure</title>
        <description>The average peak change (change score = maximum post dose score minus predose baseline) in systolic and diastolic blood pressure after nicotine infusion.</description>
        <time_frame>30 minutes after each nicotine infusion</time_frame>
        <population>Changes in heart rate, systolic and diastolic blood pressure during the experimental sessions were analyzed on all subjects who completed both experimental sessions (n=12).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Low Dose Nicotine</title>
            <description>The average peak change (change score) in systolic and diastolic blood pressure after nicotine (0.1mg per 70kg) infusion under the placebo condition.</description>
          </group>
          <group group_id="O2">
            <title>Placebo/ Medium Dose Nicotine</title>
            <description>The average peak change (change score) in systolic and diastolic blood pressure after nicotine (0.4mg per 70kg) infusion under the placebo condition.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/High Dose Nicotine</title>
            <description>The average peak change (change score) in systolic and diastolic blood pressure after nicotine (0.7mg per 70kg) infusion under the placebo condition.</description>
          </group>
          <group group_id="O4">
            <title>Varenicline/ Low Dose Nicotine</title>
            <description>The average peak change (change score) in systolic and diastolic blood pressure after nicotine (0.1mg per 70kg) infusion under the varenicline condition.</description>
          </group>
          <group group_id="O5">
            <title>Varenicline/ Medium Dose Nicotine</title>
            <description>The average peak change (change score) in systolic and diastolic blood pressure after nicotine (0.4mg per 70kg) infusion under the varenicline condition.</description>
          </group>
          <group group_id="O6">
            <title>Varenicline / High Dose Nicotine</title>
            <description>The average peak change (change score) in systolic and diastolic blood pressure after nicotine (0.7mg per 70kg) infusion under the varenicline condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Systolic and Diastolic Blood Pressure</title>
          <description>The average peak change (change score = maximum post dose score minus predose baseline) in systolic and diastolic blood pressure after nicotine infusion.</description>
          <population>Changes in heart rate, systolic and diastolic blood pressure during the experimental sessions were analyzed on all subjects who completed both experimental sessions (n=12).</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" spread="4"/>
                    <measurement group_id="O2" value="16" spread="2"/>
                    <measurement group_id="O3" value="8" spread="3"/>
                    <measurement group_id="O4" value="7" spread="2"/>
                    <measurement group_id="O5" value="13" spread="3"/>
                    <measurement group_id="O6" value="16" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="2"/>
                    <measurement group_id="O2" value="6" spread="2"/>
                    <measurement group_id="O3" value="5" spread="1"/>
                    <measurement group_id="O4" value="5" spread="2"/>
                    <measurement group_id="O5" value="6" spread="2"/>
                    <measurement group_id="O6" value="7" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo First, Then Varenicline, First Intervention</title>
          <description>Subjects received a placebo tablet once per day for 4 days prior to the first laboratory session (first intervention) where they were given ascending doses of Nicotine (0.1, 0.7mg per 70kg).</description>
        </group>
        <group group_id="E2">
          <title>Varenicline First, Then Placebo, First Intervention</title>
          <description>Subjects received varenicline once per day for 4 days prior to the first laboratory session (first intervention) where they were given ascending doses of Nicotine (0.1, 0.7mg per 70kg).</description>
        </group>
        <group group_id="E3">
          <title>Adaptation - Placebo First, Then Varenicline</title>
          <description>Subjects randomized to the 'Placebo first' condition participated in a laboratory session where they were given ascending doses of Nicotine (0.1, 0.4, 0.7mg per 70 kg) to assess tolerability prior to the study medication intervention.</description>
        </group>
        <group group_id="E4">
          <title>Adaptation - Varenicline First, Then Placebo</title>
          <description>Subjects randomized to the 'Varenicline first' condition first received a laboratory session where they were given ascending doses of Nicotine (0.1, 0.4, 0.7mg per 70 kg) to assess tolerability before receiving the study medication.</description>
        </group>
        <group group_id="E5">
          <title>Placebo First, Then Varenicline, Second Intervention</title>
          <description>Subjects crossed-over from the first intervention and received varenicline once per day for 4 days prior to the second laboratory session (second intervention) where they were given ascending doses of Nicotine (0.1, 0.7mg per 70kg).</description>
        </group>
        <group group_id="E6">
          <title>Varenicline First, Then Placebo, Second Intervention</title>
          <description>Subjects crossed-over from the first intervention (varenicline) and received placebo once per day for 4 days prior to the second laboratory session (second intervention) where they were given ascending doses of Nicotine (0.1, 0.7mg per 70kg).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mehmet Sofuoglu, M.D., Ph.D.</name_or_title>
      <organization>Yale University</organization>
      <phone>203-937-4809</phone>
      <email>mehmet.sofuoglu@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

